Trials in Progress
 |
|||
| Protein | |||
|---|---|---|---|
| NY-ESO-1 + ISCOM |
Melanoma |  |
CVC Australasia |
| NY-ESO-1 + CHP |
Prostate Breast |
 |
CVC Asia |
| NY-ESO-1 + CpG |
Prostate | |
CVC Europe |
| NY-ESO-1/ MAGE-3 + QS21/MPL + CpG |
Melanoma | |
CVC Europe CVC N.America |
| MAGE-3 + QS21/MPL |
NSCLC | |
CVC N.America |
| MAGE-3 + QS21/MPL + CpG |
NSCLC |  |
CVC Europe |
| DNA | |||
| NY-ESO-1 + rVaccinia + rFowlpox |
Melanoma Bladder | |
CVC Europe |
| NY-ESO-1 + rVaccinia + rFowlpox |
Ovarian | |
CVC N.America |
| NY-ESO-1 + PowderJect |
NSCLC | |
CVC N.America |
| Peptide | |||
| NY-ESO-1 + IFA |
Ovarian | |
CVC N.America |
| NY-ESO-1 + IFA + CpG |
NSCLC | |
CVC Europe CVC N.America |
| Melan-A + IFA + CpG |
Melanoma | |
CVC Europe |
| NY-ESO-1/ Tyrosinase/ Melan-A/ MAGE-4/ MAGE-10 + GM-CSF |
Melanoma NSCLC |
|
CVC Australasia CVC Europe CVC N.America |
| Dendritic Cells | |||
| Peptide | Melanoma | |
CVC Europe |
| NY-ESO-1 + ISCOM |
Melanoma | |
CVC Australasia |
| Immune Potentiators | |||
| CTLA.A4 | Sarcoma |  |
CVC N.America |